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Radiotherapy (RT) can induce T cell-mediated anti-tumor
immune responses by multiple mechanisms but is often
unable to overcome immunosuppression in the tumor
microenvironment. The common gamma-chain cytokines
interleukin (IL)-2 and IL-15 promote the proliferation of
activated T cells and, therefore, are prime agents for
immunotherapy strategies aimed at sustaining anti-tumor
T cell responses. The benefits of high dose IL-2, however,
are undermined by serious toxicity and by regulatory
T cell (Treg) stimulation. In contrast, IL-15 is well-toler-
ated and lacks Treg stimulatory activity, making it an
attractive candidate for testing in combination with RT.
Here we tested the hypothesis that IL-15 strengthens the
pro-immunogenic effect of local RT to potentiate a
durable anti-tumor immune response.
The poorly immunogenic mouse TSA breast cancer cells
were implanted s.c. in syngeneic BALB/c mice and ran-
domly assigned to one of 4 treatment groups when tumors
reached 5mm average diameters: control, RT, IL-15 or
RT+IL-15. RT was delivered locally in 8 Gy fractions on
days 13, 14 and 15. IL-15 (2 μg/mouse) was administered
s.c. peritumorally daily for 10 days starting on day 12.
Mice were followed for tumor growth. A parallel experi-
ment was done to characterize tumor-infiltrating lympho-
cytes (TILs) at the end of treatment (day 22).
Low dose IL-15 given peritumorally as a monotherapy
induced marginal tumor growth control and had no effect
on survival (median survival = 45 days compared to
76 days for control). Local RT significantly delayed tumor
growth (p < 0.05 compared to control) and improved
survival (median= 76 days, p < 0.05). However, highest
survival advantage was seen in mice given IL-15+RT
(median=102 days, p < 0.05 compared to all groups)
with 1 of 6 mice showing complete tumor rejection and
development of anamnestic response against tumor
re-challenge. Analysis of TILs showed marked infiltration
of CD8+ T cells expressing activation marker CD137
(35.3% in RT+IL-15 vs 5.9% in control, p < 0.05) while the
increase was modest with either monotherapy (18.8% in
RT, 20.7% in IL-15, p < 0.05 compared to control). In
addition, we found a significant increase in the ratio of
effector CD4+ T cells to Tregs (2.5 in RT+IL-15 versus
0.78 in control, p < 0.05) whereas monotherapy had no
effect (1.14 in RT, 0.96 in IL-15).
Overall these results support the rational combination of
low dose intratumoral IL-15 with local RT to re-awaken
immunity against poorly immunogenic tumors. We are
currently elucidating the mechanisms involved in pre-
clinical models in preparation for future testing in patients.
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